MYWOT
Child safety
Confidence
Trustworthiness
Confidence
MALICIOUS CONTENT INDICATORS
Q32bio.com most likely does not offer any malicious content.
Secure connection support
HTTPS
Q32bio.com provides SSL-encrypted connection.
ADULT CONTENT INDICATORS
Q32bio.com most likely does not offer any adult content.
Popular pages
-
Q32 Bio Initiates First-in-Human Phase 1 Clinical Study of ADX-097 for the Treatment of Complement
First clinical-stage program from Q32 Bio’s tissue targeted complement inhibitor platform
-
Q32 Bio Launches to Develop Novel Therapeutics Targeting Regulators of Innate and Adaptive Immunity
Proprietary tissue-targeted complement platform and best-in-class IL-7R antibody technology to treat patients with severe autoimmune and inflammatory disease; clinical trials begin in 2020
-
News & Presentations - Q32
Read more about Q32 Bio’s latest news and our upcoming events.
-
Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases - Q32
Waltham, Mass. and Dublin – August 15, 2022 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP...
-
Q32 Bio Closes $60 Million Series B Financing, Advances to Clinical Stage Research in Therapeutics
Cambridge, Mass. (October 29, 2020) – Q32 Bio, a biotechnology company developing biologic therapeutics to restore healthy immune regulation, today announced the completion of a $60 million Series B f...
-
Our Approach - Q32
Q32 Bio’s core therapeutic approach is to target the most powerful regulators of both the innate and adaptive immune systems.